FY2026 EPS Estimate for Lexeo Therapeutics Lifted by Analyst

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Stock analysts at Leerink Partnrs raised their FY2026 EPS estimates for shares of Lexeo Therapeutics in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($2.54) per share for the year, up from their previous estimate of ($2.55). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ FY2027 earnings at ($2.50) EPS.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright lifted their price target on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Leerink Partners dropped their price target on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 13th. Chardan Capital lifted their price target on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Lexeo Therapeutics has a consensus rating of “Buy” and an average target price of $23.80.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO opened at $5.58 on Friday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $184.53 million, a price-to-earnings ratio of -1.77 and a beta of 3.08. The firm’s fifty day simple moving average is $6.66 and its 200 day simple moving average is $9.28. Lexeo Therapeutics has a twelve month low of $4.67 and a twelve month high of $19.50.

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Lexeo Therapeutics in the 4th quarter worth about $46,000. SG Americas Securities LLC bought a new stake in shares of Lexeo Therapeutics in the 4th quarter worth about $72,000. JPMorgan Chase & Co. increased its position in shares of Lexeo Therapeutics by 135.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after purchasing an additional 5,915 shares during the last quarter. Exome Asset Management LLC bought a new stake in shares of Lexeo Therapeutics in the 3rd quarter worth about $797,000. Finally, Barclays PLC increased its position in shares of Lexeo Therapeutics by 162.2% in the 3rd quarter. Barclays PLC now owns 50,210 shares of the company’s stock worth $454,000 after purchasing an additional 31,057 shares during the last quarter. Institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.